← All organizations
Highest phase reached
Phase 4
First clinical trial
Apr 1, 2016Last known activity
Jul 31, 2024
Timeline
2000s
- Jan 1, 2009
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China— Founded
Drugs by trial phase (8 distinct, 18 trials)
Phase 4 (3 own, 0 via acquisition)
Phase 2 (1 own, 0 via acquisition)
Phase 1 (4 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Bronchial Fistula
- Cerebral Palsy
- Communicable Diseases
- Cytomegalovirus Infections
- Fistula
- Fractures, Bone
- Fractures, Ununited
- Hematologic Diseases
- Infections
- Infertility
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Menopause, Premature
- Muscle Spasticity
- Neoplasm, Residual
- Pancreatic Neoplasms
- Parkinson Disease
- Primary Ovarian Insufficiency
- Spinal Cord Diseases
- Tissue Adhesions
Recent trials (18)
- NCT06444022CollaboratorEarly Phase 1Jul 31, 2024
- NCT06164288Lead sponsorPhase 1Jan 1, 2024
- NCT05691114CollaboratorPhase 1Feb 28, 2023
- NCT05435755CollaboratorEarly Phase 1Dec 2, 2022
- NCT04414813CollaboratorEarly Phase 1Jun 30, 2020
- NCT04209712Lead sponsorEarly Phase 1Jan 1, 2020
- NCT03764228CollaboratorN/ADec 1, 2018
- NCT03381807CollaboratorEarly Phase 1Mar 1, 2018
- NCT03207412CollaboratorN/ADec 22, 2017
- NCT03031509CollaboratorPhase 1/Phase 2Dec 1, 2017
- NCT03223454CollaboratorPhase 1Oct 31, 2017
- NCT03107975CollaboratorPhase 1Apr 1, 2017
- NCT03004261CollaboratorPhase 4Nov 1, 2016
- NCT02959333CollaboratorPhase 1Oct 1, 2016
- NCT02912104CollaboratorPhase 1Sep 1, 2016
Details
- Founded
- Shanghai, CN Jan 1, 2009
- Last known activity
- Jul 31, 2024